Contact

Akorn Pharmaceuticals

GO
Akorn Akorn Pharmaceuticals Animal Health Akorn India Akorn Consumer Health Akorn Akorn Pharmaceuticals Animal Health Akorn India Akorn Consumer Health Akorn Akorn Pharmaceuticals Animal Health Akorn India Akorn Consumer Health
Akorn Corporate Profile

Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals as well as animal and consumer health products. We specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies.

Akorn has Research and Development facilities in Vernon Hills, IL; Cranbury, NJ; and Copiague, NY that provide a robust and continuous pipeline of new products. Akorn's manufacturing facilities are located in Decatur, IL; Somerset, NJ; Amityville, NY; Paonta Sahib, India; and Hettlingen, Switzerland.



NASDAQ:

AKRX

4.12

0

Minimum 15 minutes delayed
  • Akorn to Present at the Jefferies 2019 Global Healthcare Conference...
  • Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%...
  • Akorn to Present at the RBC Capital Markets Healthcare Conference...
  • Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance...
  • Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%...
  • Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)...

Featured Products


Ropivacaine Hydrochloride Injection, USP

Oxycodone Hydrochloride Oral Solution, USP CII

Ephedrine Sulfate Injection, USP

Ephedrine Sulfate Injection, USP

Megestrol Acetate Oral Suspension, USP

Megestrol Acetate Oral Suspension, USP

Morphine Sulfate Oral Solution, CII

Morphine Sulfate Oral Solution, CII